Literature DB >> 3953386

Interrelationships between serum levels of amiodarone, desethylamiodarone, reverse T3 and the QT interval during long-term amiodarone treatment.

J M Baerman, T Annesley, L A DiCarlo, M K Foley, J M Nicklas, B J Crevey, F Morady.   

Abstract

The interrelationships between serum levels of amiodarone, desethylamiodarone, and reverse T3, and changes in the corrected QT interval (delta QTc) were examined in 22 patients during long-term treatment with amiodarone. At 1, 3, and 6 months of follow-up, the correlation coefficient between serum levels of amiodarone or desethylamiodarone and reverse T3 ranged from 0.01 to -0.2 (p greater than 0.4). At the same time intervals, the correlation coefficient between both amiodarone and desethylamiodarone levels and delta QTc ranged from 0.1 to -0.1 (p greater than 0.6), and the correlation coefficient between reverse T3 and delta QTc also ranged between 0.1 to -0.1 (p greater than 0.5). Substituting percent delta QTc for delta QTc also did not reveal a significant correlation. These data demonstrate that serum levels of reverse T3 cannot be used as a substitute for serum levels of amiodarone in monitoring patients being treated with amiodarone. The absence of a correlation between serum reverse T3 levels and delta QTc suggests that the delay in repolarization which occurs during amiodarone therapy is not secondary to an amiodarone-induced abnormality in thyroid hormone metabolism.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3953386     DOI: 10.1016/0002-8703(86)90092-x

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  2 in total

1.  Heart rate and catecholamine contribution to QT interval shortening on exercise.

Authors:  P Davey; J Bateman
Journal:  Clin Cardiol       Date:  1999-08       Impact factor: 2.882

2.  Long-term amiodarone therapy raises serum cholesterol.

Authors:  A A Lakhdar; E Farish; W S Hillis; F G Dunn
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.